- 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
- 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
- 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
- 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
- 如果EPS衰退,要觀察同業是不是有一樣的狀況
- 要留意增資減資和公司債對股本及EPS的影響
| 加權平均股數 QoQ YoY | EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | 營收 QoQ YoY | 毛利率(%) QoQ YoY | 營業利益率 QoQ YoY | 稅後淨利率 QoQ YoY | 營業利益 QoQ YoY | 稅後淨利 QoQ YoY | 稅前淨利率(%) QoQ YoY | 稅後淨利率(%) QoQ YoY | 兩季平均(YOY)營收成長率(%) | 兩季平均(YOY)EPS成長率(%) | 兩季平均(YOY)本業EPS成長率(%) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 95 | 0.0 | 0.0 | 2.99 | -24.3 | 1968.75 | 2.05 | 55.3 | 1.49 | 2.99 | -80.22 | 1968.75 | 10.74 | 4.47 | 9.93 | 49.50 | 26.28 | 2.61 | 25.40 | 45.64 | 4.92 | 27.34 | -26.03 | 1087.0 | 2.73 | 52.51 | 15.19 | 2.85 | -24.2 | 2000.0 | 33.78 | -19.3 | 1014.85 | 27.34 | -26.03 | 1087.0 | -0.08 | -31.44 | 66.84 |
| 25Q4 (7) | 95 | 0.0 | 0.0 | 3.95 | -38.57 | -2.71 | 1.32 | 78.38 | 3.94 | 15.12 | 35.36 | 24.44 | 10.28 | -4.64 | -11.91 | 39.20 | -1.61 | -16.51 | 17.44 | 18.96 | -5.27 | 36.96 | -36.95 | 5.63 | 1.79 | 13.29 | -16.74 | 3.76 | -38.76 | -3.09 | 41.86 | -35.74 | 1.41 | 36.96 | -36.95 | 5.63 | -4.24 | -3.68 | 0.57 |
| 25Q3 (6) | 95 | 0.0 | 0.0 | 6.43 | 31.22 | 524.27 | 0.74 | -77.23 | -72.39 | 11.17 | 135.65 | 38.07 | 10.78 | -3.84 | -12.5 | 39.84 | -28.93 | -16.55 | 14.66 | -57.02 | -42.08 | 58.62 | 37.41 | 621.92 | 1.58 | -58.64 | -49.36 | 6.14 | 31.48 | 520.2 | 65.14 | 35.2 | 416.16 | 58.62 | 37.41 | 621.92 | 5.45 | 1596.86 | -8.17 |
| 25Q2 (5) | 95 | 0.0 | 0.0 | 4.90 | 3162.5 | 74.38 | 3.25 | 60.89 | 301.23 | 4.74 | 3062.5 | -32.77 | 11.21 | 14.74 | -3.61 | 56.06 | 16.21 | 31.13 | 34.11 | 40.89 | 148.8 | 42.66 | 1640.07 | 77.82 | 3.82 | 61.18 | 140.25 | 4.67 | 3213.33 | 74.25 | 48.18 | 1490.1 | 60.12 | 42.66 | 1640.07 | 77.82 | - | - | 0.00 |
| 25Q1 (4) | 95 | 0.0 | 0.0 | -0.16 | -103.94 | 0.0 | 2.02 | 59.06 | 0.0 | -0.16 | -101.32 | 0.0 | 9.77 | -16.28 | 0.0 | 48.24 | 2.75 | 0.0 | 24.21 | 31.5 | 0.0 | -2.77 | -107.92 | 0.0 | 2.37 | 10.23 | 0.0 | -0.15 | -103.87 | 0.0 | 3.03 | -92.66 | 0.0 | -2.77 | -107.92 | 0.0 | - | - | 0.00 |
| 24Q4 (3) | 95 | 0.0 | 0.0 | 4.06 | 294.17 | 0.0 | 1.27 | -52.61 | 0.0 | 12.15 | 50.19 | 0.0 | 11.67 | -5.28 | 0.0 | 46.95 | -1.65 | 0.0 | 18.41 | -27.26 | 0.0 | 34.99 | 330.91 | 0.0 | 2.15 | -31.09 | 0.0 | 3.88 | 291.92 | 0.0 | 41.28 | 227.1 | 0.0 | 34.99 | 330.91 | 0.0 | - | - | 0.00 |
| 24Q3 (2) | 95 | 0.0 | 0.0 | 1.03 | -63.35 | 0.0 | 2.68 | 230.86 | 0.0 | 8.09 | 14.75 | 0.0 | 12.32 | 5.93 | 0.0 | 47.74 | 11.67 | 0.0 | 25.31 | 84.61 | 0.0 | 8.12 | -66.15 | 0.0 | 3.12 | 96.23 | 0.0 | 0.99 | -63.06 | 0.0 | 12.62 | -58.06 | 0.0 | 8.12 | -66.15 | 0.0 | - | - | 0.00 |
| 24Q2 (1) | 95 | 0.0 | 0.0 | 2.81 | 0.0 | 0.0 | 0.81 | 0.0 | 0.0 | 7.05 | 0.0 | 0.0 | 11.63 | 0.0 | 0.0 | 42.75 | 0.0 | 0.0 | 13.71 | 0.0 | 0.0 | 23.99 | 0.0 | 0.0 | 1.59 | 0.0 | 0.0 | 2.68 | 0.0 | 0.0 | 30.09 | 0.0 | 0.0 | 23.99 | 0.0 | 0.0 | - | - | 0.00 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 3.68 | -17.09 | -6.18 | 14.43 | 5.35 | 10.74 | N/A | - | ||
| 2026/3 | 4.44 | 69.44 | 48.7 | 10.74 | 9.99 | 10.74 | 1.19 | - | ||
| 2026/2 | 2.62 | -28.8 | -15.63 | 6.3 | -7.05 | 10.38 | 1.23 | - | ||
| 2026/1 | 3.68 | -9.69 | 0.2 | 3.68 | 0.2 | 11.11 | 1.15 | - | ||
| 2025/12 | 4.08 | 21.75 | 6.27 | 42.04 | -9.41 | 10.28 | 1.23 | - | ||
| 2025/11 | 3.35 | 17.16 | -13.87 | 37.96 | -10.82 | 9.93 | 1.28 | - | ||
| 2025/10 | 2.86 | -23.19 | -27.62 | 34.62 | -10.51 | 9.36 | 1.35 | - | ||
| 2025/9 | 3.72 | 33.65 | -15.77 | 31.76 | -8.57 | 10.78 | 1.21 | - | ||
| 2025/8 | 2.78 | -34.89 | -25.95 | 28.04 | -7.52 | 10.59 | 1.23 | - | ||
| 2025/7 | 4.28 | 21.17 | 3.21 | 25.25 | -4.91 | 11.56 | 1.13 | - | ||
| 2025/6 | 3.53 | -6.09 | -9.81 | 20.98 | -6.41 | 11.21 | 1.24 | - | ||
| 2025/5 | 3.76 | -4.26 | -1.09 | 17.45 | -5.7 | 10.67 | 1.3 | - | ||
| 2025/4 | 3.92 | 31.4 | 0.03 | 13.69 | -6.89 | 10.02 | 1.39 | - | ||
| 2025/3 | 2.99 | -3.87 | -19.75 | 9.77 | -9.41 | 9.77 | 1.3 | - | ||
| 2025/2 | 3.11 | -15.43 | 8.63 | 6.78 | -3.96 | 10.62 | 1.2 | - | ||
| 2025/1 | 3.67 | -4.21 | -12.54 | 3.67 | -12.54 | 11.4 | 1.11 | - | ||
| 2024/12 | 3.84 | -1.32 | 14.4 | 46.41 | -3.45 | 11.67 | 1.04 | - | ||
| 2024/11 | 3.89 | -1.54 | 9.44 | 42.57 | -4.79 | 12.25 | 0.99 | - | ||
| 2024/10 | 3.95 | -10.61 | 1.76 | 38.69 | -6.02 | 12.13 | 1.0 | - | ||
| 2024/9 | 4.42 | 17.49 | 20.88 | 34.74 | -6.83 | 12.32 | 0.98 | - | ||
| 2024/8 | 3.76 | -9.24 | 25.92 | 30.32 | -9.84 | 11.81 | 1.02 | - | ||
| 2024/7 | 4.14 | 5.88 | 23.09 | 26.56 | -13.32 | 11.85 | 1.01 | - | ||
| 2024/6 | 3.91 | 2.98 | -0.28 | 22.42 | -17.82 | 11.63 | 1.01 | - | ||
| 2024/5 | 3.8 | -3.17 | -18.47 | 18.51 | -20.76 | 11.44 | 1.03 | - | ||
| 2024/4 | 3.92 | 5.41 | 17.54 | 14.71 | -21.33 | 10.51 | 1.12 | - | ||
| 2024/3 | 3.72 | 30.13 | -9.7 | 10.78 | -29.78 | 10.78 | N/A | - | ||
| 2024/2 | 2.86 | -31.92 | -34.99 | 7.06 | -37.15 | 10.41 | N/A | - | ||
| 2024/1 | 4.2 | 25.29 | -38.54 | 4.2 | -38.54 | 11.11 | N/A | - | ||
| 2023/12 | 3.35 | -5.6 | -30.61 | 48.07 | -50.06 | 10.78 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/11 | 3.55 | -8.45 | -14.07 | 44.72 | -51.09 | 11.09 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/10 | 3.88 | 6.17 | -57.59 | 41.16 | -52.84 | 10.52 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/9 | 3.65 | 22.38 | -42.53 | 37.28 | -52.29 | 10.01 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/8 | 2.99 | -11.28 | -45.91 | 33.63 | -53.15 | 10.27 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/7 | 3.37 | -14.21 | -72.1 | 30.64 | -53.75 | 11.95 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/6 | 3.92 | -15.79 | -66.77 | 27.28 | -49.67 | 11.92 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/5 | 4.66 | 39.59 | -61.39 | 23.36 | -44.91 | 12.12 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/4 | 3.34 | -19.02 | -73.08 | 18.7 | -38.35 | 11.86 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/3 | 4.12 | -6.31 | -27.24 | 15.36 | -14.33 | 15.36 | N/A | - | ||
| 2023/2 | 4.4 | -35.64 | -8.69 | 11.24 | -8.37 | 16.07 | N/A | - | ||
| 2023/1 | 6.84 | 41.47 | -8.16 | 6.84 | -8.16 | 15.8 | N/A | - | ||
| 2022/12 | 4.83 | 16.89 | 8.63 | 96.27 | 48.25 | 18.12 | N/A | - | ||
| 2022/11 | 4.13 | -54.82 | -20.82 | 91.44 | 51.17 | 19.64 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/10 | 9.15 | 43.9 | 127.2 | 87.3 | 57.97 | 21.03 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/9 | 6.36 | 15.18 | -4.76 | 78.15 | 52.53 | 23.95 | N/A | 本年係因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/8 | 5.52 | -54.24 | -24.57 | 71.79 | 61.11 | 29.39 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2022/7 | 12.07 | 2.19 | 72.45 | 66.27 | 77.96 | 35.94 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/6 | 11.81 | -2.16 | 30.83 | 54.21 | 79.23 | 36.28 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/5 | 12.07 | -2.68 | 171.06 | 42.4 | 99.81 | 30.14 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/4 | 12.4 | 118.89 | 275.69 | 30.33 | 80.89 | 22.89 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/3 | 5.67 | 17.57 | 31.04 | 17.93 | 33.14 | 17.93 | N/A | - | ||
| 2022/2 | 4.82 | -35.27 | 25.38 | 12.26 | 34.13 | 16.71 | N/A | - | ||
| 2022/1 | 7.44 | 67.35 | 40.48 | 7.44 | 40.48 | 17.11 | N/A | - | ||
| 2021/12 | 4.45 | -14.79 | -21.26 | 64.93 | 10.15 | 13.7 | N/A | - | ||
| 2021/11 | 5.22 | 29.62 | 35.73 | 60.48 | 13.48 | 15.93 | N/A | - | ||
| 2021/10 | 4.03 | -39.68 | -9.57 | 55.26 | 11.75 | 18.02 | N/A | - | ||
| 2021/9 | 6.68 | -8.76 | 22.75 | 51.24 | 13.86 | 20.99 | N/A | - | ||
| 2021/8 | 7.32 | 4.61 | 69.1 | 44.56 | 12.64 | 23.34 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2021/7 | 7.0 | -22.47 | 34.32 | 37.24 | 5.7 | 20.47 | N/A | - | ||
| 2021/6 | 9.02 | 102.68 | 93.22 | 30.24 | 0.74 | 0.0 | N/A | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2021/5 | 4.45 | 34.88 | -30.03 | 21.22 | -16.29 | 0.0 | N/A | - |
| 加權平均股數 YoY | EPS YoY | 本業EPS YoY | 營收 YoY | 毛利率(%) YoY | 營業利益率 YoY | 稅後淨利率 YoY | 營業利益 YoY | 稅前淨利 YoY | 稅後淨利 YoY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 95 | 0.0 | 15.02 | 24.75 | 7.33 | 38.04 | 42.04 | -9.42 | 45.96 | 3.84 | 22.74 | 30.09 | 34.80 | 34.26 | 9.56 | 17.88 | 17.02 | 16.1 | 14.42 | 24.42 |
| 2024 (4) | 95 | 0.0 | 12.04 | 13.37 | 5.31 | -23.27 | 46.41 | -3.45 | 44.26 | 2.64 | 17.48 | -13.21 | 25.92 | 18.36 | 8.11 | -16.22 | 14.66 | 10.39 | 11.59 | 13.96 |
| 2023 (3) | 95 | 1.06 | 10.62 | -69.74 | 6.92 | -79.16 | 48.07 | -50.07 | 43.12 | -26.48 | 20.14 | -53.17 | 21.90 | -39.22 | 9.68 | -76.62 | 13.28 | -69.6 | 10.17 | -69.94 |
| 2022 (2) | 94 | 1.08 | 35.10 | 70.31 | 33.21 | 102.5 | 96.27 | 48.27 | 58.65 | 18.68 | 43.01 | 33.28 | 36.03 | 14.45 | 41.41 | 97.66 | 43.69 | 73.93 | 33.83 | 71.29 |
| 2021 (1) | 93 | 4.49 | 20.61 | 25.98 | 16.40 | 2.56 | 64.93 | 9.98 | 49.42 | 0 | 32.27 | 0 | 31.48 | 0 | 20.95 | 5.7 | 25.12 | 26.61 | 19.75 | 29.85 |